Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iron therapy Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effect of H. Pylori Infection on Iron Metabolism

NCT00202488
View directory record Official record
Conditions
Iron Deficiency Anemia, Helicobacter Pylori Infection
Interventions
H. pylori treatment
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

NCT02409459
View directory record Official record
Conditions
Iron Deficiency, Fibromyalgia
Interventions
Injectafer, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 23, 2026, 4:59 PM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

NCT02435212
View directory record Official record
Conditions
Transfusion-dependent Anemia
Interventions
Deferasirox granule formulation, Deferasirox DT formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Oakland, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

NCT01155388
View directory record Official record
Conditions
Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

NCT01090323
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
31
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
View directory record Official record
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

NCT03029208
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779
View directory record Official record
Conditions
Iron Deficiency, Anemia, Kidney Disease
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Interventions
Ferric maltol, Placebo
Drug · Other
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
27
States / cities
Peoria, Arizona • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

NCT01309659
View directory record Official record
Conditions
Anemia, Unexplained Anemia (UAE)
Interventions
iron sucrose
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 23, 2026, 4:59 PM EDT
Completed No phase listed Observational

IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

NCT05153278
View directory record Official record
Conditions
Iron Deficiency Anemia Treatment, Iron-deficiency, Iron Deficiency Anemia Due to Blood Loss, Iron Deficiency Anemia
Interventions
Packed red blood cells, Intravenous drug
Biological · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia

NCT01114217
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03238911
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

NCT03637556
View directory record Official record
Conditions
Thalassemia Major
Interventions
DST-0509, Jadenu, Exjade
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
8 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617
View directory record Official record
Conditions
Sickle Cell Disease, Iron Overload, Hemolytic Anemia
Interventions
Deferasirox (ICL670), Deferoxamine (DFO)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

NCT02636049
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated No phase listed Observational

AIH Risk Stratification With Multiparametric MRI

NCT04339621
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
LiverMultiscan
Device
Lead sponsor
Perspectum
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Phase 4 Interventional

Oral Iron in Children With Chronic Kidney Disease

NCT03991169
View directory record Official record
Conditions
Chronic Kidney Insufficiency, Chronic Kidney Diseases
Interventions
Ferrous Sulfate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

NCT01227616
View directory record Official record
Conditions
Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
38
States / cities
Pine Bluff, Arkansas • Azusa, California • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Iron Depletion Therapy for Type 2 DM and NAFLD

NCT00230087
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions
blood donation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

NCT01604941
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
SPD602
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 23, 2026, 4:59 PM EDT